Details for Patent: 10,208,307
✉ Email this page to a colleague
Which drugs does patent 10,208,307 protect, and when does it expire?
Patent 10,208,307 protects AMVUTTRA and is included in one NDA.
This patent has sixty-three patent family members in thirty-seven countries.
Summary for Patent: 10,208,307
| Title: | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
| Abstract: | The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases. |
| Inventor(s): | Tracy Zimmermann, Amy Chan, Vasant Jadhav, Martin Maier, Kallanthottathil G. Rajeev |
| Assignee: | Alnylam Pharmaceuticals Inc |
| Application Number: | US15/221,651 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,208,307 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,208,307
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,208,307
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3329002 | ⤷ Start Trial | 301216 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3329002 | ⤷ Start Trial | PA2023505 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3329002 | ⤷ Start Trial | 7/2023 | Austria | ⤷ Start Trial |
| European Patent Office | 3329002 | ⤷ Start Trial | 2023C/507 | Belgium | ⤷ Start Trial |
| European Patent Office | 3329002 | ⤷ Start Trial | LUC00297 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3329002 | ⤷ Start Trial | CA 2023 00008 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
